---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-008810"
form_type: "8-K"
ticker: "STXS"
cik: "0001289340"
company_name: "Stereotaxis, Inc."
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T16:59:53.155745+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Q4 revenue up 39% to $6.3M; expects double-digit revenue growth in 2025

## Summary
- Q4 2024 revenue $6.3M (+39% YoY); full year $26.9M (+0.4% YoY).
- Operating loss ($7.6M) in Q4; adjusted operating loss ($4.0M); net loss ($7.5M).
- Cash $12.4M, no debt; positive free cash flow of $1.3M in Q4.
- 2025 guidance: double-digit revenue growth; recurring revenue to scale from $5M Q1 to $7M Q4.
- Regulatory milestones: European MAGiC catheter approval, GenesisX first sale, China approvals.

## SEC filing metadata
- accession: 0001493152-25-008810
- form_type: 8-K
- ticker: STXS
- cik: 0001289340
- company_name: Stereotaxis, Inc.
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1289340/000149315225008810/0001493152-25-008810-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1289340/000149315225008810/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-008810
- JSON: https://secwatch.observer/filing/0001493152-25-008810.json
- Plain text: https://secwatch.observer/filing/0001493152-25-008810.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.